OncoMatch/Clinical Trials/NCT07309185
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Is NCT07309185 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Irinotecan for stomach neoplasms.
Treatment: Adebrelimab · Irinotecan · Malic acid Famitinib — This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Metastatic disease required
advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; at least one measurable lesion that has not received local treatment such as radiotherapy (RECIST v1.1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy — first-line
previously failed first-line treatment including systemic chemotherapy
Must have received: checkpoint inhibitor — first-line
previously failed first-line treatment including...immune checkpoint inhibitors, and have maintained first-line use of immune checkpoint inhibitors for at least 3 months
Cannot have received: paclitaxel (paclitaxel)
Patients who have received previous treatment with paclitaxel drugs
Cannot have received: anti-tumor therapy
Exception: within 2 weeks prior to the first use of the investigational drug
Received anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization) within 2 weeks prior to the first use of the investigational drug
Cannot have received: investigational drug
Exception: within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug
Received any other investigational drug within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug
Cannot have received: anti-tumor vaccine
Exception: within 4 weeks prior to the first administration of the study drug
Individuals who have received anti-tumor vaccines or have received live vaccines within 4 weeks prior to the first administration of the study drug
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L
Kidney function
CrCl ≥ 60 ml/min/1.73 m2 (Cockcroft Gault formula)
Liver function
serum total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 2.5x ULN (≤ 5x ULN if liver metastasis)
The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 10^9/L (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml/min/1.73 m2 (calculated according to the Cockcroft Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify